Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Rydapt

- PMLiVE

NICE backs Lundbeck’s alcohol dependence drug Selincro

Alcoholics in England to have access to once-daily drug

- PMLiVE

The moving parts of orphan drug development

Tackling rare diseases requires high levels of cooperation, regulatory support and a determination to succeed

- PMLiVE

France wants Avastin used in place of Lucentis

Government calls for off-label use of Roche drug in order to reduce spend on eye therapy

- PMLiVE

Novartis embraces the ‘quantified self’ with TicTrac tie-up

Partners with the personalised analytics firm on a new MS platform

Novartis building

Novartis charged in Japan over data falsification

Prosecutors claim pharma company employees manipulated Diovan data

Novartis building

Novartis pulls EMA application for expanded Tasigna use

And Boehringer confirms it won't seek approval for faldaprevir as it exits hepatitis C

- PMLiVE

Novartis and NHS launch mobile eye unit in UK

First of its kind unit to offer 250 clinic slots per week across Surrey, Hampshire and Berkshire

- PMLiVE

NICE backs Janssen’s once-daily diabetes drug

Invokana is the tenth treatment recommended in England and Wales to lower blood sugar levels

National Institute for Health and Care Excellence NICE logo

NICE backs constipation treatment

Sucampo’s Amitiza set for NHS use in England and Wales

UK flag

NICE guidelines on atrial fibrillation discourage aspirin use

Health watchdog encourages greater NHS use of new anticoagulant drugs

Gilead Sciences

Sovaldi stumbles as NICE assesses hep C drug’s price

Gilead must provide much more cost-effectiveness information

National Institute for Health and Care Excellence NICE logo

NICE guidelines on statins will ‘medicalise’ the healthy, say doctors

Prominent physicians call for rethink on plans to lower treatment threshold

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links